These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 9129564

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial.
    Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J.
    Clin Pharmacol Ther; 1996 Apr; 59(4):469-75. PubMed ID: 8612393
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study.
    Yancey-Wrona J, Dallaire B, Bilsky E, Bath B, Burkart J, Webster L, Magiera D, Yang X, Phelps M, Sadee W.
    Pain Med; 2011 Dec; 12(12):1727-37. PubMed ID: 22123184
    [Abstract] [Full Text] [Related]

  • 8. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.
    Yuan CS, Doshan H, Charney MR, O'connor M, Karrison T, Maleckar SA, Israel RJ, Moss J.
    J Clin Pharmacol; 2005 May; 45(5):538-46. PubMed ID: 15831777
    [Abstract] [Full Text] [Related]

  • 9. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
    Franchi F, Rollini F, Park Y, Hu J, Kureti M, Rivas Rios J, Faz G, Yaranov D, Been L, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ.
    JACC Cardiovasc Interv; 2019 Aug 26; 12(16):1538-1549. PubMed ID: 31377269
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone.
    Moss J.
    Anesthesiology; 2019 Jan 26; 130(1):142-148. PubMed ID: 30277930
    [Abstract] [Full Text] [Related]

  • 13. Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects.
    Kolbow J, Modess C, Wegner D, Oswald S, Maritz MA, Rey H, Weitschies W, Siegmund W.
    J Clin Pharmacol; 2016 Feb 26; 56(2):239-45. PubMed ID: 26313157
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness.
    Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ.
    J Pain Symptom Manage; 2009 Nov 26; 38(5):683-90. PubMed ID: 19713070
    [Abstract] [Full Text] [Related]

  • 19. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
    Liu SS, Hodgson PS, Carpenter RL, Fricke JR.
    Clin Pharmacol Ther; 2001 Jan 26; 69(1):66-71. PubMed ID: 11180040
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.